Marinda Meertens

发表

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

E. Schuuring, E. Smit, A. Dingemans, 2023, Frontiers in Oncology.

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

H. Rosing, N. Steeghs, N. de Vries, 2024, Therapeutic drug monitoring.